Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …

OBJECTIVE Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows
an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-…

Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis,
assessment, prevention, and treatment of hypertension in adults and children. This year, …

Background: Dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2, may
improve glycemic control with a lower dose of insulin and attenuate the associated weight gain …

Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force
provides annually updated, evidence-based recommendations to guide the diagnosis, …

Hypertension Canada’s 2020 guidelines for the prevention, diagnosis, risk assessment, and
treatment of hypertension in adults and children provide comprehensive, evidence-based …

The Canadian Hypertension Education Program reviews the hypertension literature annually
and provides detailed recommendations regarding hypertension diagnosis, assessment, …

Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis,
assessment, prevention, and treatment of hypertension. This year, we introduce 10 new …

Herein, updated evidence-based recommendations for the diagnosis, assessment, prevention,
and treatment of hypertension in Canadian adults are detailed. For 2014, 3 existing …

Background A fixed-ratio combination of the basal insulin analogue insulin degludec and
the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily …